Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Yesterday, March 11, 2015, 115 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $183.00 to $317,250,000.00.

Highlighted Stocks Traded by Insiders:

VMWare (VMW) - FREE Research Report

Krysler P. Kevan, who is Sr. Vice President, CAO at VMWare, sold 3,211 shares at $85.61 on March 11, 2015. Following this transaction, the Sr. Vice President, CAO owned 28,960 shares meaning that the stake was reduced by 9.98% with the 3,211-share transaction.

The shares most recently traded at $81.26, down $4.35, or 5.35% since the insider transaction. Historical insider transactions for VMWare go as follows:

  • 4-Week # shares sold: 68,880
  • 12-Week # shares sold: 68,880
  • 24-Week # shares sold: 68,880

The average volume for VMWare has been 1.9 million shares per day over the past 30 days. VMWare has a market cap of $10.6 billion and is part of the technology sector and computer software & services industry. Shares are down 1.83% year-to-date as of the close of trading on Wednesday.

VMware, Inc. provides virtualization infrastructure solutions in the United States and internationally. The company has a P/E ratio of 40.7. Currently, there are 15 analysts who rate VMWare a buy, no analysts rate it a sell, and 11 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on VMW - FREE

TheStreet Quant Ratings

rates VMWare as a

hold

. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including disappointing return on equity, weak operating cash flow and a generally disappointing performance in the stock itself. Get the full

VMWare Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

CBIZ (CBZ) - FREE Research Report

France Gina D, who is Director at CBIZ, bought 5,000 shares at $8.79 on March 11, 2015. Following this transaction, the Director owned 16,793 shares meaning that the stake was boosted by 42.4% with the 5,000-share transaction.

The shares most recently traded at $9.05, up $0.26, or 2.87% since the insider transaction. Historical insider transactions for CBIZ go as follows:

  • 4-Week # shares bought: 10,095
  • 4-Week # shares sold: 12,000
  • 12-Week # shares bought: 10,191
  • 12-Week # shares sold: 12,000
  • 24-Week # shares bought: 10,622
  • 24-Week # shares sold: 57,000

The average volume for CBIZ has been 213,900 shares per day over the past 30 days. CBIZ has a market cap of $431.6 million and is part of the services sector and diversified services industry. Shares are up 3.97% year-to-date as of the close of trading on Wednesday.

CBIZ, Inc., through its subsidiaries, operates as a diversified services company in the United States and Canada. The company has a P/E ratio of 8.2. Currently, there are no analysts who rate CBIZ a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on CBZ - FREE

TheStreet Quant Ratings

rates CBIZ as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, impressive record of earnings per share growth, increase in net income and reasonable valuation levels. We feel these strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full

CBIZ Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Solazyme (SZYM) - FREE Research Report

Quinlan Paul T, who is General Counsel at Solazyme, sold 9,687 shares at $2.69 on March 11, 2015. Following this transaction, the General Counsel owned 79,879 shares meaning that the stake was reduced by 10.82% with the 9,687-share transaction.

Licari Peter, who is Chief Technology Officer at Solazyme, sold 19,062 shares at $2.69 on March 11, 2015. Following this transaction, the Chief Technology Officer owned 175,529 shares meaning that the stake was reduced by 9.8% with the 19,062-share transaction.

Painter Tyler, who is CFO and COO at Solazyme, sold 19,062 shares at $2.69 on March 11, 2015. Following this transaction, the CFO and COO owned 407,000 shares meaning that the stake was reduced by 4.47% with the 19,062-share transaction.

The shares most recently traded at $3.14, up $0.45, or 14.18% since the insider transaction. Historical insider transactions for Solazyme go as follows:

  • 4-Week # shares sold: 150,624
  • 12-Week # shares sold: 150,624
  • 24-Week # shares sold: 150,624

The average volume for Solazyme has been 990,700 shares per day over the past 30 days. Solazyme has a market cap of $218.9 million and is part of the basic materials sector and chemicals industry. Shares are up 22.87% year-to-date as of the close of trading on Wednesday.

Solazyme, Inc. manufactures and sells renewable oils and other bioproducts. Its proprietary technology transforms a range of plant-based sugars into triglyceride oils and other bioproducts. Currently, there are 3 analysts who rate Solazyme a buy, 1 analyst rates it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on SZYM - FREE

TheStreet Quant Ratings

rates Solazyme as a

sell

. The company's weaknesses can be seen in multiple areas, such as its generally high debt management risk, disappointing return on equity, generally disappointing historical performance in the stock itself, deteriorating net income and feeble growth in its earnings per share. Get the full

Solazyme Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

null